In 2020 an estimated 9.9 million people fell ill with TB. Among these, 132,222 cases of MDR/RR-TB and 25,681 cases of pre-XDR-TB or XDR-TB were detected, giving a combined total of 157,903. Worldwide 150,359 people with MDR/RR-TB were enrolled on treatment in 2020. Multidrug-resistant TB (MDR TB) is caused by Mycobacterium Tuberculosis that are resistant to at least isoniazid and rifampicin, the two most potent TB drugs. To build up the regime for MDRTB is easy, however, to maintain a patient on a regime is challenging. An ideal regime should consist of efficacious drugs, short duration, less pill burden, no injectable drugs, low cost of treatment, less adverse drug reaction with excellent treatment success. Recently, WHO has published a new recommendation on all-oral treatment for MDRTB based on TB PRACTECAL and ZeNIX trial which showed excellent success rate of >90%. Finally, there is a hope in MDRTB treatment. However more researches are needed, hence, the theme of world TB day 2022-‘INVEST TO END TB. SAVE LIVES’.